AR076607A1 - Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo - Google Patents

Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo

Info

Publication number
AR076607A1
AR076607A1 ARP100101845A ARP100101845A AR076607A1 AR 076607 A1 AR076607 A1 AR 076607A1 AR P100101845 A ARP100101845 A AR P100101845A AR P100101845 A ARP100101845 A AR P100101845A AR 076607 A1 AR076607 A1 AR 076607A1
Authority
AR
Argentina
Prior art keywords
composition
producing
lgg
highly concentrated
concentrated preparation
Prior art date
Application number
ARP100101845A
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Teschner
Theresa Friederike Bauer
Bernhard Koelbl
Hans-Peter Schwarz
Azra Pljevljakovic
Nebojsa Nikiloc
Gerhard Polsler
Harald Arno Butterweck
Johanna Kindermann
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR076607A1 publication Critical patent/AR076607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ARP100101845A 2009-05-27 2010-05-27 Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo AR076607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18160609P 2009-05-27 2009-05-27

Publications (1)

Publication Number Publication Date
AR076607A1 true AR076607A1 (es) 2011-06-22

Family

ID=42335649

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101845A AR076607A1 (es) 2009-05-27 2010-05-27 Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo

Country Status (18)

Country Link
US (5) US8546548B2 (https=)
EP (3) EP2762492A3 (https=)
JP (1) JP5341252B2 (https=)
KR (1) KR101464032B1 (https=)
CN (1) CN102459331B (https=)
AR (1) AR076607A1 (https=)
AU (6) AU2010253830B2 (https=)
BR (1) BRPI1012082B1 (https=)
CA (1) CA2763138A1 (https=)
CL (2) CL2011002996A1 (https=)
CO (1) CO6480954A2 (https=)
EA (1) EA023382B1 (https=)
HK (1) HK1200843A1 (https=)
MX (1) MX2011012576A (https=)
MY (1) MY157239A (https=)
SG (1) SG176256A1 (https=)
TW (1) TWI445714B (https=)
WO (1) WO2010138736A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
MX2011012576A (es) * 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
CA2810731A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
US9403899B2 (en) 2011-08-26 2016-08-02 Baxalta Incorporated Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
AU2012321074B2 (en) 2011-12-13 2015-12-03 Takeda Pharmaceutical Company Limited Measurement of autoantibodies at low conductivity conditions with increased sensitivity
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
EP2873422A4 (en) * 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
CA2901225C (en) 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
MX380902B (es) * 2013-11-15 2025-03-12 Genentech Inc Métodos para la inactivación viral usando detergentes ecológico.
CN108026507A (zh) * 2015-04-02 2018-05-11 K·黄 由组分vi制造afod静脉注射剂的方法
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
EP3955962A4 (en) * 2019-04-18 2022-12-14 Momenta Pharmaceuticals, Inc. SIALYLATED GLYCOPROTEINS
EP4490179A1 (en) 2022-03-07 2025-01-15 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
CN117069836B (zh) * 2023-09-22 2024-08-27 武汉中生毓晋生物医药有限责任公司 一种抗人t细胞兔免疫球蛋白的制备方法
WO2025068923A2 (en) * 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3929411A1 (de) 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
US4892826A (en) 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
NZ509135A (en) * 1998-06-09 2002-10-25 Statens Seruminstitut A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
WO2005023867A1 (en) 2003-09-08 2005-03-17 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
JP2008500959A (ja) * 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
CN1922207B (zh) 2004-02-27 2012-06-06 奥克特珐玛股份有限公司 提供纯化的、病毒安全的抗体制剂的方法
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
CN101279246B (zh) * 2007-12-28 2011-07-27 华侨大学 一种嗜硫性磁性复合微球的制备方法和用此复合微球分离免疫球蛋白g的方法
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
MX2011012576A (es) * 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.

Also Published As

Publication number Publication date
AU2010253830A1 (en) 2011-12-15
HK1200843A1 (en) 2015-08-14
SG176256A1 (en) 2012-01-30
KR101464032B1 (ko) 2014-11-27
US8546548B2 (en) 2013-10-01
AU2020204244B2 (en) 2022-08-18
BRPI1012082B1 (pt) 2022-08-16
EP3708581A1 (en) 2020-09-16
CN102459331B (zh) 2015-01-28
US20220153823A1 (en) 2022-05-19
US20100330071A1 (en) 2010-12-30
US11242380B2 (en) 2022-02-08
AU2010253830B2 (en) 2016-03-03
CL2013001673A1 (es) 2013-12-06
EP2762492A3 (en) 2015-03-18
US20160244512A1 (en) 2016-08-25
EP2762492A2 (en) 2014-08-06
MY157239A (en) 2016-05-13
AU2020204244A1 (en) 2020-07-16
CN102459331A (zh) 2012-05-16
US10125189B2 (en) 2018-11-13
EP2435474A2 (en) 2012-04-04
WO2010138736A3 (en) 2011-03-17
CO6480954A2 (es) 2012-07-16
EP3708581A3 (en) 2021-10-20
BRPI1012082A2 (pt) 2019-04-02
JP5341252B2 (ja) 2013-11-13
EA201171481A1 (ru) 2012-07-30
WO2010138736A2 (en) 2010-12-02
JP2012528190A (ja) 2012-11-12
AU2024203600A1 (en) 2024-06-20
EA023382B1 (ru) 2016-05-31
MX2011012576A (es) 2012-05-08
AU2018200548B2 (en) 2020-04-02
AU2022228125A1 (en) 2022-09-29
CA2763138A1 (en) 2010-12-02
AU2016203542B2 (en) 2018-02-15
AU2016203542A1 (en) 2016-06-16
KR20140014403A (ko) 2014-02-06
TWI445714B (zh) 2014-07-21
AU2022228125B2 (en) 2024-02-29
TW201107344A (en) 2011-03-01
US20190085064A1 (en) 2019-03-21
CL2011002996A1 (es) 2012-10-19
US9175068B2 (en) 2015-11-03
AU2018200548A1 (en) 2018-02-15
US20140030252A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
AR076607A1 (es) Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo
Chauhan et al. Role of Th17 cells in the immunopathogenesis of dry eye disease
EP4600271A3 (en) Bioactive molecule conjugate, preparation method and use thereof
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
RU2009148886A (ru) Рсв-специфичные связывающие молекулы и средства для их получения
US11672833B2 (en) Edible bird's nest extract and method of extraction
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
MX2010005276A (es) Proceso de esterilizacion por filtracion en estado diluido para biopolimeros viscoelasticos.
EA202191753A1 (ru) Синтетические и рекомбинантно полученные коллагеновые пептиды, имеющие биологическую активность
MX2015004290A (es) Formulacion que contiene virus y uso de la misma.
FR2969495B1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
BR112015006929A2 (pt) sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
WO2017043953A3 (es) Proceso de obtención de un compuesto de aspersión de células endoteliales microvasculares de piel y células madre mesenquimales y su método de aplicación para la regeneración tisular
EA201691790A1 (ru) Способ получения продукта глатирамера ацетата
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
CO2022012868A2 (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
CL2024002627A1 (es) Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.
ITPD20050206A1 (it) Biomateriali in forma di fibra da impiegarsi come dispositivi medici nel trattamento delle ferite e loro processi di produzione
ATE284209T1 (de) Verwendung einer pharmazeutischen zusammensetzung zur herstellung eines medikamentes zur behandlung von durch bakterien, viren, pilze, hefen und/oder protozoen verursachten augenerkrankungen
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
BR112022021092A2 (pt) Composições e métodos para vacinação e tratamento de doenças infecciosas
CN111956516A (zh) 免水洗抗菌香氛组合物及其制备方法
EP4491231A3 (en) Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
CN107998186A (zh) 一种针对抑郁症的组合物

Legal Events

Date Code Title Description
FG Grant, registration